CTi Biopharma Corp Financials

CTICDelisted Stock  USD 9.09  0.00  0.00%   
Based on the key measurements obtained from CTi Biopharma's financial statements, CTi Biopharma Corp is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.
  
Understanding current and past CTi Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CTi Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in CTi Biopharma's assets may result in an increase in income on the income statement.
Please note, the presentation of CTi Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CTi Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CTi Biopharma's management manipulating its earnings.

CTi Biopharma Stock Summary

CTi Biopharma competes with Rigel Pharmaceuticals, Fortress Biotech, Reviva Pharmaceuticals, Protalix Biotherapeutics, and Seres Therapeutics. CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. Cti Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS12648L6011
Business Address3101 Western Avenue,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.ctibiopharma.com
Phone206 282 7100
CurrencyUSD - US Dollar

CTi Biopharma Key Financial Ratios

CTi Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining CTi Biopharma's current stock value. Our valuation model uses many indicators to compare CTi Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CTi Biopharma competition to find correlations between indicators driving CTi Biopharma's intrinsic value. More Info.
CTi Biopharma Corp is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CTi Biopharma's earnings, one of the primary drivers of an investment's value.

CTi Biopharma Market Pulse

 Quote9.09
 Change(%) 0.00  
 Change0.00 
 Open9.09
 Low9.09
 High9.09
 Volume0
 ExchangeNASDAQ

About CTi Biopharma Financials

What exactly are CTi Biopharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include CTi Biopharma's income statement, its balance sheet, and the statement of cash flows. Potential CTi Biopharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although CTi Biopharma investors may use each financial statement separately, they are all related. The changes in CTi Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CTi Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

CTi Biopharma November 27, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of CTi Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CTi Biopharma Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of CTi Biopharma Corp based on widely used predictive technical indicators. In general, we focus on analyzing CTi Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CTi Biopharma's daily price indicators and compare them against related drivers.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Consideration for investing in CTi Stock

If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance